Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Investigating the Impact of Tumor Necrosis Factor Inhibitors on SARS-CoV-2 mRNA Vaccine-induced Immunity in Immunocompromised Patients with Immune-mediated Inflammatory Diseases
EF 2022-23
Résumé
Immunocompromised patients are at increased risk of viral infections and adverse outcomes following infection, including intensive care unit admission and in-hospital mortality. Further, they run the risk of shedding virus for longer, leading to increased risk of transmission or the generation of immune escape variants. While vaccination reduces the risk of infection in immunocompromised patients, it may be less effective in patients treated with immunomodulatory or immunosuppressive therapies. In this study, we will focus on immunocompromised adult patients with inflammatory bowel disease (IBD). Patients with IBD are often treated with drugs that block an inflammatory molecule called tumor necrosis factor (TNF). Treatment with TNF blocking agents is known to impair antibody responses to vaccines developed for seasonal influenza and SARS-CoV-2. In this proposal, we will conduct an in-depth investigation of the immune cells (T and B cells) in these treated IBD patients to further understand the detailed mechanism driving the defect in antibody responses to SARS-CoV-2 mRNA vaccination and how we can counteract the defect. Our studies will fill a critical gap in understanding how immunosuppressive treatments, such as TNF blockers, affect the immune response of immunocompromised patients to SARS-CoV-2 vaccination, with broader implications to other viral vaccines. Importantly, we hope to inform public policy on the optimal vaccine development and regimens for the immunocompromised.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
475681
Name
Cheung Michelle W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the Impact of Tumor Necrosis Factor Inhibitors on SARS-CoV-2 mRNA Vaccine-induced Immunity in Immunocompromised Patients with Immune-mediated Inflammatory Diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immunity; Bnt162b2 Sars-Cov-2 Vaccine; Cite-Sequencing; Covid-19; Immune-Mediated Inflammatory Diseases; Immunocompromised Patients; Mrna-1273 Sars-Cov-2 Vaccine; Severe Acute Respiratory Syndrome Coronavirus 2; Tumor Necrosis Factor Inhibitors
Abstract
Immunocompromised patients are at increased risk of viral infections and adverse outcomes following infection, including intensive care unit admission and in-hospital mortality. Further, they run the risk of shedding virus for longer, leading to increased risk of transmission or the generation of immune escape variants. While vaccination reduces the risk of infection in immunocompromised patients, it may be less effective in patients treated with immunomodulatory or immunosuppressive therapies. In this study, we will focus on immunocompromised adult patients with inflammatory bowel disease (IBD). Patients with IBD are often treated with drugs that block an inflammatory molecule called tumor necrosis factor (TNF). Treatment with TNF blocking agents is known to impair antibody responses to vaccines developed for seasonal influenza and SARS-CoV-2. In this proposal, we will conduct an in-depth investigation of the immune cells (T and B cells) in these treated IBD patients to further understand the detailed mechanism driving the defect in antibody responses to SARS-CoV-2 mRNA vaccination and how we can counteract the defect. Our studies will fill a critical gap in understanding how immunosuppressive treatments, such as TNF blockers, affect the immune response of immunocompromised patients to SARS-CoV-2 vaccination, with broader implications to other viral vaccines. Importantly, we hope to inform public policy on the optimal vaccine development and regimens for the immunocompromised.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cheung, Michelle W
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~